Kira Pharmaceuticals, a global clinical-stage biotechnology company, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to KP104 for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a rare, life-threatening blood disease that arises due to hyperactivity of the complement system. An intricate constellation of protein pathways, the complement system is a key component of innate immunity. Aberrant activity within this system can be a driver of diseases such as autoimmune and inflammatory conditions. KP104 is a bifunctional, first-in-class biologic with a unique dual-approach mechanism of action. Designed to selectively block the alternative and terminal pathways, KP104 provides a powerful and synergistic method of targeting validated drivers of disease in the complement system. KP104 has also been engineered to have an extended half-life and potency, with a formulation that can be used for both IV and subcutaneous administration.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!